A 43-year-old man with chronic active hepatitis C was treated with interferon-p (IFN-(3) at a dosage of 6xlO6 IU/day for a planned 6-week period. Ocular hyperemia, ophthalmalgia, and increased intraocular pressure in the right eye developed 20 days after the start of treatment. Intraocular pressure remained high, even after discontinuation of IFN therapy, laser therapy, and iridectomy. T\yo days later, the right eye was removed because perforation had occurred. The ocular symptomsthat developed in this case were thought to have been caused and exacerbated by IFN administration. (Internal Medicine 35: 15-18, 1996) 
Introduction
Interferon (IFN) is widely used to treat malignant tumors and viral infectious diseases. A variety of adverse effects have been reported (1) (2) (3) . Although serious ocular adverse reactions (4-6) have not been reported, several cases of troubling ophthalmologic adverse effects, principally retinal disorders, have been noted. Wereport a case of a patient in whomretrobulbar and intraocular hemorrhage developed which resulted in loss of vision, presumably as a result of IFN administration.
Case Report
A 43-year-old man had been treated for chronic hepatitis in our outpatient department since 1979 after his liver function was found to be abnormal. In July 1993, the patient was admitted to the hospital to undergo a liver biopsy followed by IFN treatment because tests for hepatitis C virus (HCV) antibodies and HCV-RNA were positive and transaminase levels had been persistently elevated during the 3-year period prior to admission. The patient's past and family histories were unremarkable. There was no history of ophthalmologic disorders, including glaucoma, nor had the patient received a blood transfusion. Physical examination upon admission revealed no striking abnormalities except that the liver was elastic, firm, palpable one finger-breadth below the right costal margin, and had a dull edge.
Results of laboratory examinations upon admission were normal except for mild increases in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and IgG (Table 1) . No autoantibodies were detected in serum. Both hepatitis B surface antigen and antibody to HBsantigen were negative. However, both HCVantibody and HCV-RNAwere positive. Retention of indocyanine green was 9%, which is within the normal range ( Table 2) . Pathologic examination of a biopsy specimen obtained after hospitalization showed infiltration of lymphocytes and piecemeal necrosis (Fig. 1) .
On the basis of these findings, a diagnosis of chronic active hepatitis C was made, and a 6-week course of IFN-p therapy, 6 million units/day, was started. During the course of treatment, serum ASTand ALTlevels decreased satisfactorily, and the knownadverse reactions to IFN of mild decreases in leukocyte and platelet counts were also noted. Other symptomsincluded tolerable headache, malaise, and a fever of about 38°C, which could be controlled by antipyretic analgesics. Twenty days after the start of treatment ocular hyperemia, ophthalmalgia, and increased intraocular pressure in the right eye suddenly developed and gradually worsened. The patient was transferred to our ophthalmology unit.
The initial ophthalmologic consultation revealed ciliary injection, a shallow anterior chamber, and ocular hypertension of 44 mmHgin the right eye, leading to a diagnosis of acute glaucoma.
Although IFN was discontinued and infusion of an ocular hypotensive agent was begun, intraocular pressure remained high at 75 mmHg. Laser therapy was performed. Since the patient's intraocular pressure increased to 77 mmHg, and the symptoms, including ophthalmalgia, continued to worsen, iridectomy was performed (Fig. 2) . A computed tomography scan of the brain, performed 2 days after the appearance of ocular symptoms, disclosed exophthalmos, an indistinct margin of the eyeball, and a hypertrophic optic nerve (Fig. 3) . The ophthalmalgia gradually decreased, but the intraocular pressure (Fig. 4) and ocular deformity, blurring, and destruction (Fig. 5) . Ocular rupture resulting from keratomalacia occurred, with leakage of the intraocular contents, including viscous blood and exudate (Fig. 6 ). For these reasons, right ocular Intraocular HemorrhageDeveloping during Interferon Therapy thy (4) (5) (6) . Despite several reports of IFN-induced retinopathy causing impairment of visual acuity (12) , most cases of IFN toxicity are mild. To the best of our knowledge, there have been no previous reports of retrobulbar or intraocular hemorrhage resulting in acute ocular dysfunction. According to Miyamoto et al (6) , gradually progressive retinopathy may occur after 1 to 3 months ofIFN treatment, but this adverse effect is usually resolved after withdrawal of the drug. However, the ocular disorder which developed in the present patient, occurring after only 20 days of treatment with rapidly progressive symptoms that necessitated enucleation, is not consistent with IFN-induced retinopathy. Furthermore, the major predisposing factor in IFN-induced retinopathy is believed to be diabetes mellitus. Anemia, thrombocytopenia, and elevated serum triglyceride levels are also commonlyknown risk factors (13) . In the present patient however, the laboratory examinations revealed no evidence of diabetes mellitus, thrombocytopenia, or anemia in. Although retinal hemorrhage is a principal symptom ofIFN-induced retinopathy, our patient' s presenting symptom was glaucoma. Moreover, the cause of glaucoma was thought to be a sudden rise in intraocular pressure due to pathologic mechanical obstruction of the drainage of the anterior chamber fluid in the angle, i.e., a result of ophthalmologic disorders caused by tumor, inflammation, trauma, or neovascularization. Nevertheless, an ophthalmologic disorder that commonlycauses glaucomawas not present in our patient.
Wetherefore assume that the sudden increase in intraocular pressure and resulting symptomswere a result of compression of the eyeball by retrobulbar and intraocular hemorrhage.
In conclusion, since IFN administration may produce retrobulbar and intraocular hemorrhage leading to glaucoma in patients with chronic active hepatitis C, it is important to carefully monitor the ophthalmologic status throghout IFN therapy.
